What Is LSD?
Lysergic acid diethylamide — LSD, or "acid" — is a semi-synthetic psychedelic compound first synthesized by Swiss chemist Albert Hofmann at Sandoz Laboratories in 1938. Hofmann was searching for a respiratory stimulant derived from ergot fungus (Claviceps purpurea), which grows on rye and other grains. He set the compound aside, and five years later, on April 19, 1943, accidentally absorbed a small amount through his fingertips and experienced the world's first intentional LSD trip — a bicycle ride home through Basel that became known as "Bicycle Day."
LSD is extraordinarily potent. Active doses are measured in micrograms (millionths of a gram) — typically 75–200 micrograms for a full psychedelic experience. It is odorless, colorless, and tasteless, and is typically distributed on blotter paper, in liquid form, or as micro-dots.
From 1943 to 1968, LSD was used in over 1,000 published clinical studies involving more than 40,000 patients, with researchers reporting remarkable results for alcoholism, anxiety, depression, and end-of-life distress. Sandoz distributed LSD freely to researchers under the trade name Delysid. The CIA conducted its own (deeply unethical) research program — MKUltra — dosing unwitting subjects in an attempt to develop mind control techniques.
The counterculture of the 1960s embraced LSD as a tool for consciousness expansion, and its association with anti-war protest and social upheaval led President Nixon to classify it as Schedule I in 1970 — effectively ending clinical research for three decades. Today, LSD research is resuming at institutions including Johns Hopkins, Imperial College London, and the University of Zurich.
The Neuroscience
LSD acts primarily on serotonin receptors, particularly the 5-HT2A receptor — the same primary target as psilocybin and mescaline. However, LSD has an unusually complex pharmacological profile, binding to over a dozen receptor types including dopamine, adrenergic, and histamine receptors. This complexity may explain why LSD experiences are often described as more stimulating and cognitively complex than psilocybin.
A key feature of LSD's pharmacology is its "kinetic selectivity" — it binds to the 5-HT2A receptor and then becomes trapped inside it, which is why LSD experiences last 8–12 hours compared to 4–6 hours for psilocybin. The receptor essentially closes around the LSD molecule, creating a prolonged effect.
Like other classic psychedelics, LSD dramatically reduces activity in the Default Mode Network and increases global brain connectivity. A landmark 2016 study from Imperial College London using fMRI and MEG imaging found that LSD produced a dramatic increase in the diversity of brain states — a measure of "neural complexity" — that correlated directly with the subjective intensity of the experience. This increased complexity is thought to reflect a temporary dissolution of the brain's normal hierarchical organization, allowing new patterns of thought and perception to emerge.
LSD also promotes neuroplasticity and synaptogenesis (the formation of new synaptic connections), which may underlie its lasting effects on mood, perspective, and behavior.
What to Expect
An LSD experience typically begins 30–90 minutes after ingestion and lasts 8–12 hours, with a gradual come-down over several additional hours. The extended duration distinguishes it from most other psychedelics and makes set, setting, and preparation especially important.
At lower doses (50–75 micrograms), effects are mild: enhanced colors and patterns, heightened sensory awareness, increased sociability, and a sense of mental clarity and openness. Many people use these doses for creative work or personal exploration.
At therapeutic doses (100–200 micrograms), the experience becomes more profound. Visual phenomena intensify — geometric patterns, trails, and transformations of surfaces. Thinking becomes non-linear and associative. Emotional content rises to the surface. The sense of time distorts dramatically — hours may feel like minutes or lifetimes. Insights about patterns, relationships, and self often emerge with unusual clarity and force.
LSD experiences tend to be more cognitively active and stimulating than psilocybin — the mind remains engaged and analytical even at high doses, which some people find valuable and others find overwhelming. The extended duration means that difficult material has more time to be processed — but also more time to become challenging if the experience turns difficult.
The importance of set (mindset) and setting (environment) cannot be overstated with LSD. The experience amplifies whatever emotional state you bring to it. Anxiety, unresolved conflict, and fear of losing control can all become magnified. Careful preparation and a trusted, experienced guide are essential for therapeutic use.
Conditions It Addresses
The early clinical research on LSD (1950s–1960s) produced remarkable results that were largely forgotten after prohibition. The current research renaissance is rediscovering and extending these findings:
Alcoholism: The most robust finding from the early research era. A 2012 meta-analysis of six randomized controlled trials from the 1960s and 1970s found that a single dose of LSD produced a significant reduction in alcohol misuse — with effects comparable to the best current treatments. A 2022 Norwegian study replicated these findings.
Anxiety and Depression: Early studies showed significant reductions in anxiety and depression across multiple populations. Current research at Johns Hopkins and Imperial College London is actively investigating LSD for treatment-resistant depression.
End-of-Life Anxiety: A 2014 Swiss study — the first therapeutic LSD research in 40 years — found that LSD-assisted psychotherapy significantly reduced anxiety in patients with life-threatening illness, with effects persisting at 12-month follow-up.
Cluster Headaches: Anecdotal reports and small studies suggest that LSD (and psilocybin) can abort cluster headache cycles — a finding that has led to a dedicated research program at Yale University.
Addiction: Beyond alcohol, early research showed promise for opioid and other substance use disorders. Current research is ongoing.
Safety Profile
LSD is physiologically non-toxic at doses used for psychedelic experiences. There are no documented cases of fatal overdose from LSD alone. It does not produce physical dependence or withdrawal.
The primary risks are psychological. LSD can trigger prolonged anxiety states, psychosis, or HPPD (Hallucinogen Persisting Perception Disorder) — particularly in people with a personal or family history of psychosis, schizophrenia, or bipolar disorder. These conditions are absolute contraindications.
The extended duration of LSD (8–12 hours) means that a difficult experience has more time to develop and intensify. This makes experienced facilitation especially important for therapeutic use.
LSD does not have significant dangerous drug interactions, but combining it with lithium is contraindicated (risk of seizures), and combining it with SSRIs may reduce or block effects.
In a therapeutic setting with proper screening, preparation, and support, LSD has an excellent safety record. The risks are primarily from unsupervised recreational use in inappropriate settings.
Legal Status
LSD is a Schedule I controlled substance under US federal law and is illegal in most countries worldwide.
Research exceptions exist: LSD research is conducted under DEA Schedule I researcher licenses at Johns Hopkins, Imperial College London, University of Zurich, and other institutions.
Switzerland has a special historical relationship with LSD — it was synthesized there, and Swiss authorities have been more permissive of research. The Multidisciplinary Association for Psychedelic Studies (MAPS) has conducted LSD research in Switzerland.
No state has decriminalized or legalized LSD specifically, though several cities (Denver, Oakland, Washington D.C.) have passed broad measures deprioritizing enforcement of psychedelic possession laws.
At Pō a Ao, we do not offer LSD therapy. We include this information as part of our commitment to comprehensive psychedelic medicine education.